The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Even as Novo Nordisk and Eli Lilly found themselves unable to fully serve demand, they still brought in billions of dollars ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the ...

Pharmaceutical executives and public health experts have warned that Robert F Kennedy jnr’s influence over Donald Trump could ...

That may leave some Americans to question whether they'll find their local stores, banks, post offices, DMV and other services open on November 5. At the same time, some schools are closed on Election ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Novo Nordisk is paying $55 million upfront to secure ... In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use. The launch environment ...

CENTRAL GOVERNMENT FUNDS: Social welfare would account for the largest portion of the NT$3.33 trillion budget, followed by spending on education, tech and culture ...